Cleared Traditional

K240169 - Stellaris Elite vision enhancement syst...

K240169 is an FDA 510(k) clearance for Stellaris Elite vision enhancement syst..., manufactured by Bausch and Lomb, Incorporated. The device is a Class 2 Ophthalmic device with product code HQC cleared through the Traditional 510(k) pathway after a 186-day FDA review.

K240169 · Bausch and Lomb, Incorporated · Ophthalmic device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jul 2024
Decision
186d
Days
Class 2
Risk

K240169 is an FDA 510(k) clearance for the Stellaris Elite vision enhancement system (BL11145, BL14455, BL15455). Classified as Unit, Phacofragmentation (product code HQC), Class II - Special Controls.

Submitted by Bausch and Lomb, Incorporated (St. Louis, US). The FDA issued a Cleared decision on July 26, 2024 after a review of 186 days - an extended review cycle.

This device falls under the Ophthalmic FDA review panel, regulated under 21 CFR 886.4670 - the FDA ophthalmic device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Ophthalmic review framework, consistent with the majority of Class II 510(k) submissions.

View all Bausch and Lomb, Incorporated devices

FDA 510(k) Submission Details - K240169

510(k) Number K240169 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 22, 2024
Decision Date July 26, 2024
Days to Decision 186 days
Submission Type Traditional
Review Panel Ophthalmic (OP)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
76d slower than avg
Panel avg: 110d · This submission: 186d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

HQC Device Classification - Class 2, Special Controls

Product Code HQC Unit, Phacofragmentation
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 886.4670
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Ophthalmic devices follow this clearance model.

Regulatory Peers - HQC Unit, Phacofragmentation

All 121
Devices cleared under the same product code (HQC) and FDA review panel - the closest regulatory comparables to K240169.
System Sophi
K250501 · This AG · Nov 2025
MICOR 700 with Auto I/A
K243395 · Carl Zeiss Meditec Cataract Technology, Inc. · Aug 2025
MICOR 700 System (N/A)
K242801 · Carl Zeiss Meditec Cataract Technology, Inc. · Jun 2025
Faros Surgical System
K233398 · Oertli Instrumente AG · Jun 2024
UNITY VCS (8065000296)
K233876 · Alcon Laboratories, Inc. · Jun 2024
Stellaris Elite vision enhancement system
K232084 · Bausch and Lomb · Feb 2024